124750-67-0

Basic information

• Product Name: 2-n-Butyl-4-chloro-1-[(2'-cyanobiphenyl-4-yl)methyl]imidazole-5-carboxaldehyde
• Synonyms: 2-n-Butyl-4-chloro-1-[(2'-cyanobiphenyl-4-yl)methyl]imidazole-5-carboxaldehyde
• CAS NO: 124750-67-0
• Molecular Weight: 377.873
• Mol File: 124750-67-0.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: 2-n-Butyl-4-chloro-1-[(2'-cyanobiphenyl-4-yl)methyl]imidazole-5-carboxaldehyde(CAS DataBase Reference)
• NIST Chemistry Reference: 2-n-Butyl-4-chloro-1-[(2'-cyanobiphenyl-4-yl)methyl]imidazole-5-carboxaldehyde(124750-67-0)
• EPA Substance Registry System: 2-n-Butyl-4-chloro-1-[(2'-cyanobiphenyl-4-yl)methyl]imidazole-5-carboxaldehyde(124750-67-0)

Safety Data

• Hazardous Substances Data: 124750-67-0(Hazardous Substances Data)

Upstream product

• 83857-96-9 2-n-butyl-4-chloro-1H-imidazol-5-carboxaldehyde 
• 114772-54-2 4'-(bromomethyl)-1,1'-biphenyl-2-carbonitrile 
• 84392-32-5 4,4-dimethyl-2-(4'-methyl-biphenyl-2-yl)-4,5-dihydrooxazole 
• 114772-34-8 methyl 4'-methylbiphenyl-2-carboxylate 
• 79047-41-9 2-n-butyl-4-chloro-5-hydroxymethylimidazole 
• 7148-03-0 o-tolylbenzoic acid 
• 106-38-7 para-bromotoluene 
• 57598-33-1 2-(2-methoxyphenyl)-4,4-dimethyl-2-oxazoline 
• 114772-53-1 2-Cyano-4'-methylbiphenyl 
• 696-61-7 4-tolylmagnesium chloride 
• 873-32-5 2-Chlorobenzonitrile 
• 57246-71-6 methyl pentanimidate 
• 193140-43-1 (pentanimidoylamino)acetic acid 
• 110-59-8 pentanonitrile 

Downstream Products

• 124750-99-8 cozaar 
• 114798-26-4 2-n-butyl-4-chloro-5-hydroxymethyl-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]imidazole 
• 114798-26-4 lorsartan 
• 124750-99-8 losartan potassium 
• 114798-36-6 2-n-Butyl-4-chloro-1-[(2'-(1H-tetrazol-5-yl)biphenyl-4-yl)methyl]-imidazole-5-carboxaldehyde 
• 114798-36-6 EXP 3179 
• 124750-68-1 2-n-Butyl-4-chloro-5-cyano-1-[(2'-cyanobiphenyl-4-yl)methyl]imidazole 
• 114772-55-3 2-n-Butyl-4-chloro-1-[(2'-cyanobiphenyl-4-yl)-methyl]-5-(hydroxymethyl)imidazole 

Relevant articles and documents

Preparation method of losartan

The invention provides a preparation method of losartan. The losartan is prepared by reacting a cyano-containing intermediate as shown in a formula (I), which is described in the specification, with an azide reagent in toluene in the presence of a catalyst. After the reaction is finished, azide ions are removed through the following procedures: adding water to divide a reaction system into three layers, separating out a middle layer, adding n-butyl alcohol into the middle layer for dilution, and adding triphenylphosphine into the obtained diluted solution to remove the residual azide ions in the diluted solution. According to the preparation method, sodium nitrite is not needed, so formation of the genotoxic impurity nitrosamine is fundamentally eradicated; the obtained target losartan isgood in purity and high in yield; and the method is simple and convenient in preparation process, mild and easily controllable in operation conditions, good in safety, and suitable for large-scale industrial production.

COMPOUNDS AS MODULATOR OF JAK-STAT PATHWAY, METHODS AND APPLICATIONS THEREOF

The present disclosure relates to compound of structural Formula I and a method for preparing said compounds. The disclosure further relates to a method of employing the Formula I compounds for modulation of Janus kinase-Signal Transducer and Activator of Transcription (JAK-STAT) pathway in cancer cells, and the corresponding use of compound of Formula I as anti-cancer agents.

An efficient, commercially viable, and safe process for preparation of losartan potassium, an angiotensin II receptor antagonist

An efficient, commercially viable and safe process for the preparation of losartan potassium, an antihypertensive drug substance, with an overall yield of 55.5% and ～99.9% purity (including five chemical reactions and two recrystallizations) and meeting all other regulatory requirements is described. Formation and control of all the possible impurities are also described.